Delta-THC in Behavioral Disturbances in Dementia
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Dementia is a common chronic condition, with predicted increasing prevalence. Nearly all patients with dementia will experience neuropsychiatric symptoms (NPS). This causes significant burden for the individual patients and their caregivers. Current treatment has only modest efficacy and important side-effects. Formulations with Δ9-tetrahydrocannabinol (THC), the psycho-active compound of cannabis, are currently being registered for spasms in multiple sclerosis and other diseases, and may have beneficial effects on NPS.
| Condition | Intervention | Phase |
|---|---|---|
|
Dementia |
Drug: Delta-THC Drug: placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Two Phase, Repeated Crossover Study With Dose Escalation on Delta(9)-Tetrahydrocannabinol (Delta-THC) in Behavioral Disturbances in Dementia |
- Neuropsychiatric Inventory (NPI) [ Time Frame: At day 3 and 10 during treatment blocks and after 1 month, 3 months and 6 months in the open label extension phase ] [ Designated as safety issue: No ]Improvement in behavior compared to placebo is measured with the NPI, which is the standard measure of Neuro Psychiatric Symptoms in most clinical trials.
- Cohen-Mansfield Agitation Inventory (CMAI) [ Time Frame: At days 1, 3, 8, and 10 during treatment blocks 1 and 4 and weekly during treatment blocks 2, 3, 5 and 6 and months 1, 3, 6 and 6 during extension phase ] [ Designated as safety issue: No ]Improvement in agitation compared to placebo and during long term treatment is measured with CMAI. It is useful in determining fluctuations in behaviors and emotional states in Alzheimer's Disease
- Zarit Burden Scale (ZBS) [ Time Frame: At days 3 and 10 during treatment blocks and months 1, 3 and 6 during extension phase ] [ Designated as safety issue: No ]Reducing caregiver stress compared to placebo and during long term treatment by focusing on the patients' behavior compared to Zarit burden interviews with the caregiver.
- Visual Analogue Scale (VAS) Bowdle for feeling high [ Time Frame: At days 1, 3, 8, and 10 during treatment blocks 1 and 4 and weekly during treatment blocks 2, 3, 5 and 6 and months 1, 3, 6 and 6 during extension phase ] [ Designated as safety issue: Yes ]severity and duration of feeling high episodes
- Gait rite® [ Time Frame: At days 1 and 8 during blocks 1 and 4 and at 1, 3 and 6 months during extension phase ] [ Designated as safety issue: Yes ]Improvement and/or safety compared to placebo and during long term treatment on balance and mobility. It is a non invasive and highly feasible mobility assessment.
- Sway Star® [ Time Frame: At days 1 and 8 during blocks 1 and 4 and at 1, 3 and 6 months during extension phase ] [ Designated as safety issue: Yes ]Improvement and/or safety compared to placebo and during long term treatment on balance and mobility. It is a non invasive and highly feasible mobility assessments.
- Time up and go [ Time Frame: At days 1, 3, 8, and 10 during treatment blocks 1 and 4 and weekly during treatment blocks 2, 3, 5 and 6 and months 1, 3, 6 and 6 during extension phase ] [ Designated as safety issue: Yes ]Improvement and/or safety compared to placebo and during long term treatment on balance and mobility in elderly patients.
- Tinetti [ Time Frame: At days 1, 3, 8, and 10 during treatment blocks 1 and 4 and weekly during treatment blocks 2, 3, 5 and 6 and months 1, 3, 6 and 6 during extension phase ] [ Designated as safety issue: Yes ]Improvement and/or safety compared to placebo and during long term treatment on balance and mobility in elderly patients. It is a performance-oriented assessment of mobility problems in elderly patients.
- pharmacogenetics [ Time Frame: day 1 ] [ Designated as safety issue: No ]
The following polymorphisms will be genotyped:
- CYP2C9*2
- CYP2C9*3
- CYP2C19*2
- CYP2C19*3
- CYP2C19*17
To investigate the role of CYP2C9 and CYP2C19 genetic polymorphisms in the interindividual variation in pharmacokinetics, efficacy and adverse events of THC.
| Estimated Enrollment: | 20 |
| Study Start Date: | September 2011 |
| Estimated Study Completion Date: | March 2014 |
| Estimated Primary Completion Date: | November 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Delta-THC
At hospital admission Delta-THC will be administered during three days.
|
Drug: Delta-THC
First treatment period: During 3 days of hospital admission, 2 times daily 1 tablet of 0.75 mg delta-THC will be administered after which a 4 day washout period applies. Thereafter the cross over starts. This will be repeated two times but then without hospital admission.
Other Names:
Drug: Delta-THC
If first treatment period is safe, the second treatment period starts: during 3 days of hospital admission, 2 times daily 1 tablet of 1.5 mg delta-THC will be administered after which a 4 day washout period applies. Thereafter the cross over starts. This will be repeated two times but then without hospital admission.
Other Names:
Drug: Delta-THC
In case either 2 times daily 1 tablet 0,75mg or 2 times daily 1 tablet 1.5mg Delta-THC appeared to be efficacious for a particular patient, this patient can continue the effective dose of delta-THC in an open label extension phase during 6 months.
Other Names:
|
|
Placebo Comparator: placebo
At hospital admission placebo will be administered during three days.
|
Drug: placebo
During 3 days of hospital admission, 2 times daily 1 tablet of placebo will be administered after which a 4 day washout period applies. Thereafter the cross over starts. This will be repeated two times but then without hospital admission during the first treatment period. If the first period appeared to be safe, this same intervention will be repeated during the second treatment period.
Other Name: Placebo Namisol
|
Detailed Description:
Design Phase II pilot study, multi-center, repeated cross-over, double blinded randomized trial. Consisting out of 6 blocks of 2 weeks, after 3 blocks (period A) the dose will increase after safety evaluation by the physician responsible for the patient. Each block consists out of active treatment and placebo, within between a wash-out period. After the two treatment periods, subjects will proceed to the extension phase if applicable.
Study centers The department of Geriatrics from Radboud University Nijmegen Medical Centre and the department of Elderly from Vincent van Gogh voor Geestelijke Gezondheidszorg Venray (VVG) will participate in this multi center study.
Participants 20 subjects with dementia and NPS. Intervention Namisol® in doses of twice daily 0,75 mg tablet (period A) and twice daily 1.5 mg (period B) THC oral tablets. Placebo of twice daily 0,75 mg and twice daily 1.5 mg oral tablets Outcome measures Primary outcome is NPI score, secondary CMAI, Zarit Burden scale. Other outcomes include vital signs, side-effects, physical exam, mobility and pharmacogenetics.
Visits This study will be assessed fully ambulatory, starting with a 5 hour clinical visit on day 1 and 8 of block 1 and a phone call on day 2 and 9 for assessment of Adverse Events. Furthermore, the research physician will conduct a weekly home visit weekly during the crossover phase for assessment of , among others, the primary outcome measure. These visits will all be repeated in period B of the crossover phase.
During the 6 month open label extension phase, subjects will visit the clinic three times.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of Alzheimer's Disease (AD), Vascular Dementia (VD) or mixed, according to the criteria of NINCDS-ADRDA or NINCDS-AIREN
- Clinical Dementia Rating score between 0.5 and 3
- NPS symptoms, with at least agitation or aggression
Exclusion Criteria:
- Diagnosis of Lewy Body Dementia (LBD) or Fronto-Temporal Dementia (FTD)
- Major psychiatric disorder
- Severe concomitant illness, seizure, arrhythmias (except sinus arrhythmia and atrial fibrillation), heart failure New York Heart Association (NYHA) class III or IV
- Tri Cyclic Antidepressives (TCA) or opioids used within 30 days before randomization till the end of the study
- Changes in dosage of antidepressives within 6 weeks before randomization and during study, and changes in dosage antipsychotics or benzodiazepines within 2 weeks prior to randomization and during study
Contacts and Locations| Contact: Marcel Olde Rikkert, prof MD | +31 24 3616772 | M.Olde-Rikkert@ger.umcn.nl |
| Contact: Geke van den Elsen, MD | +31 24 3613912 | G.vandenElsen@ger.umcn.nl |
| Netherlands | |
| Radboud Universitey Medical Center Nijmegen | Recruiting |
| Nijmegen, Gelderland, Netherlands, 6525EX | |
| Contact: Marcel Olde Rikkert, Prof MD +31 24 3616772 M.Olde-Rikkert@ger.umcn.nl | |
| Contact: Geke van den Elsen, MD +31 24 3666317 G.vandenElsen@ger.umcn.nl | |
| Principal Investigator: Marcel Olde Rikkert, prof MD | |
| Sub-Investigator: Geke Elsen, van den, MD | |
| Vincent van Gogh Institute for Psychiatry, department of Elderly | Not yet recruiting |
| Venray, Limburg, Netherlands, 5803 | |
| Contact: Amir Ahmed, MD +31 478 527527 A.Ahmed@ger.umcn.nl | |
| Principal Investigator: Willem Verhoeven, prof MD | |
| Sub-Investigator: Amir Ahmed, MD | |
| Principal Investigator: | Marcel Olde Rikkert, prof MD | Radboud University Medical Center Nijmegen |
More Information
No publications provided
| Responsible Party: | Marcel Olde Rikkert, Prof. dr., Radboud University |
| ClinicalTrials.gov Identifier: | NCT01302340 History of Changes |
| Other Study ID Numbers: | GER001-02-01, 2009-019329, 2010-024577-39, Supplies Investigational Drug |
| Study First Received: | February 10, 2011 |
| Last Updated: | February 11, 2013 |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Keywords provided by Radboud University:
|
Dementia Alzheimer Cannabis |
THC Behavioral Disturbances Neuropsychiatric Inventory |
Additional relevant MeSH terms:
|
Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Tetrahydrocannabinol Hallucinogens Physiological Effects of Drugs |
Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Psychotropic Drugs Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents |
ClinicalTrials.gov processed this record on May 16, 2013